Session

IBD (Posters)

AGE MAY NOT IMPACT BIOLOGIC TREATMENT FAILURE AT 12 MONTHS FOR INFLAMMATORY BOWEL DISEASE: A REAL LIFE RETROSPECTIVE SINGLE CENTRE COHORT STUDY
AGE MAY NOT IMPACT BIOLOGIC TREATMENT FAILURE AT 12 MONTHS FOR INFLAMMATORY BOWEL DISEASE: A REAL LIFE RETROSPECTIVE SINGLE CENTRE COHORT STUDY

THE USE OF PANENTERIC CROHN'S CAPSULES TO ASSESS TREATMENT OUTCOME OF VEDOLIZUMAB IN IBD PATIENTS: A 1 YEAR PROOF OF CONCEPT STUDY
THE USE OF PANENTERIC CROHN'S CAPSULES TO ASSESS TREATMENT OUTCOME OF VEDOLIZUMAB IN IBD PATIENTS: A 1 YEAR PROOF OF CONCEPT STUDY

A REAL-WORLD EVALUATION OF TOFACITINIB FOR ULCERATIVE COLITIS IN UK AND IRELAND
A REAL-WORLD EVALUATION OF TOFACITINIB FOR ULCERATIVE COLITIS IN UK AND IRELAND

REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE COSTS AMONG US COMMERCIALLY INSURED ADULTS INITIATING BIOLOGICS FOR ULCERATIVE COLITIS
REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE COSTS AMONG US COMMERCIALLY INSURED ADULTS INITIATING BIOLOGICS FOR ULCERATIVE COLITIS

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE
REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

SERUM INFLIXIMAB CONCENTRATIONS DURING INDUCTION PREDICT SHORT-TERM TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SERUM INFLIXIMAB CONCENTRATIONS DURING INDUCTION PREDICT SHORT-TERM TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN'S DISEASE: ECUFIT STUDY FROM GETECCU
LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN'S DISEASE: ECUFIT STUDY FROM GETECCU

EFFECTS OF COVID-19 ON TREATMENT AND PATIENT MANAGEMENT IN INFLAMMATORY BOWEL DISEASE: FINDINGS FROM A REAL-WORLD SURVEY IN EUROPE
EFFECTS OF COVID-19 ON TREATMENT AND PATIENT MANAGEMENT IN INFLAMMATORY BOWEL DISEASE: FINDINGS FROM A REAL-WORLD SURVEY IN EUROPE

AN AUDIT OF PROACTIVE THERAPEUTIC DRUG MONITORING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGICS
AN AUDIT OF PROACTIVE THERAPEUTIC DRUG MONITORING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGICS

THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH
THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH

VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE
VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE

IMPACT OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS AND THEIR FAMILIES ACCORDING TO DISEASE CONTROL
IMPACT OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS AND THEIR FAMILIES ACCORDING TO DISEASE CONTROL

CHANGE IN URGENCY AMONG CROHN'S DISEASE PATIENTS: ANALYSES FROM THE SPARC IBD
CHANGE IN URGENCY AMONG CROHN'S DISEASE PATIENTS: ANALYSES FROM THE SPARC IBD

CORRELATION OF EX VIVO MUCOSAL CYTOKINE PROFILES WITH CLINICAL AND ENDOSCOPIC SCORES IN ULCERATIVE COLITIS
CORRELATION OF EX VIVO MUCOSAL CYTOKINE PROFILES WITH CLINICAL AND ENDOSCOPIC SCORES IN ULCERATIVE COLITIS

SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

ASSOCIATION BETWEEN SERUM VITAMIN D METABOLITES AND HEMATOLOGICAL MARKERS OF INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
ASSOCIATION BETWEEN SERUM VITAMIN D METABOLITES AND HEMATOLOGICAL MARKERS OF INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PRESENCE OF THE HLA-DQA1*05 ALLELE AND ITS ASSOCIATION WITH THE SECONDARY LOSS OF RESPONSE TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PRESENCE OF THE HLA-DQA1*05 ALLELE AND ITS ASSOCIATION WITH THE SECONDARY LOSS OF RESPONSE TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

VEDOLIZUMAB IN REAL PRACTICE: EXPERIENCE IN A TERTIARY HOSPITAL
VEDOLIZUMAB IN REAL PRACTICE: EXPERIENCE IN A TERTIARY HOSPITAL

Item 201 - 220 / 568
1 2 3 4 5 6 7 8 9 10
11
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29